Immunohistochemical expression of epidermal growth factor receptor in breast cancer

Tadahiro Nozoe, Emiko Mori, Tomohiro Iguchi, Akinori Egashira, Eisuke Adachi, Akito Matsukuma, Takahiro Ezaki

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Molecular-targeting drugs able to treat breast cancer expressing epidermal growth factor receptor (EGFR) would be clinically valuable. The aim of the current study was to determine the further significance of immunohistochemical expression of EGFR in breast cancer. Methods: The immunohistochemical expression of EGFR was examined in 37 women with breast cancer who had been treated with surgical resection. Relationship of EGFR expression and clinicopathological characteristics was investigated. Results: EGFR expression proved to be comparatively more frequent among triple-negative (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative) breast cancers (P = 0.067). Conclusions: Knowledge of a patient's immunohistochemical EGFR expression, which could be one of the key molecular findings related to molecular-targeting therapy, might be useful information to treat triple-negative breast cancer.

Original languageEnglish
Pages (from-to)37-41
Number of pages5
JournalBreast Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 1 2011

Fingerprint

Epidermal Growth Factor Receptor
Breast Neoplasms
Triple Negative Breast Neoplasms
Progesterone Receptors
Drug Delivery Systems
Estrogen Receptors

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Nozoe, T., Mori, E., Iguchi, T., Egashira, A., Adachi, E., Matsukuma, A., & Ezaki, T. (2011). Immunohistochemical expression of epidermal growth factor receptor in breast cancer. Breast Cancer, 18(1), 37-41. https://doi.org/10.1007/s12282-010-0200-2

Immunohistochemical expression of epidermal growth factor receptor in breast cancer. / Nozoe, Tadahiro; Mori, Emiko; Iguchi, Tomohiro; Egashira, Akinori; Adachi, Eisuke; Matsukuma, Akito; Ezaki, Takahiro.

In: Breast Cancer, Vol. 18, No. 1, 01.01.2011, p. 37-41.

Research output: Contribution to journalArticle

Nozoe, T, Mori, E, Iguchi, T, Egashira, A, Adachi, E, Matsukuma, A & Ezaki, T 2011, 'Immunohistochemical expression of epidermal growth factor receptor in breast cancer', Breast Cancer, vol. 18, no. 1, pp. 37-41. https://doi.org/10.1007/s12282-010-0200-2
Nozoe T, Mori E, Iguchi T, Egashira A, Adachi E, Matsukuma A et al. Immunohistochemical expression of epidermal growth factor receptor in breast cancer. Breast Cancer. 2011 Jan 1;18(1):37-41. https://doi.org/10.1007/s12282-010-0200-2
Nozoe, Tadahiro ; Mori, Emiko ; Iguchi, Tomohiro ; Egashira, Akinori ; Adachi, Eisuke ; Matsukuma, Akito ; Ezaki, Takahiro. / Immunohistochemical expression of epidermal growth factor receptor in breast cancer. In: Breast Cancer. 2011 ; Vol. 18, No. 1. pp. 37-41.
@article{16532238ae1548b890880cbf04ace2a0,
title = "Immunohistochemical expression of epidermal growth factor receptor in breast cancer",
abstract = "Background: Molecular-targeting drugs able to treat breast cancer expressing epidermal growth factor receptor (EGFR) would be clinically valuable. The aim of the current study was to determine the further significance of immunohistochemical expression of EGFR in breast cancer. Methods: The immunohistochemical expression of EGFR was examined in 37 women with breast cancer who had been treated with surgical resection. Relationship of EGFR expression and clinicopathological characteristics was investigated. Results: EGFR expression proved to be comparatively more frequent among triple-negative (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative) breast cancers (P = 0.067). Conclusions: Knowledge of a patient's immunohistochemical EGFR expression, which could be one of the key molecular findings related to molecular-targeting therapy, might be useful information to treat triple-negative breast cancer.",
author = "Tadahiro Nozoe and Emiko Mori and Tomohiro Iguchi and Akinori Egashira and Eisuke Adachi and Akito Matsukuma and Takahiro Ezaki",
year = "2011",
month = "1",
day = "1",
doi = "10.1007/s12282-010-0200-2",
language = "English",
volume = "18",
pages = "37--41",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Immunohistochemical expression of epidermal growth factor receptor in breast cancer

AU - Nozoe, Tadahiro

AU - Mori, Emiko

AU - Iguchi, Tomohiro

AU - Egashira, Akinori

AU - Adachi, Eisuke

AU - Matsukuma, Akito

AU - Ezaki, Takahiro

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: Molecular-targeting drugs able to treat breast cancer expressing epidermal growth factor receptor (EGFR) would be clinically valuable. The aim of the current study was to determine the further significance of immunohistochemical expression of EGFR in breast cancer. Methods: The immunohistochemical expression of EGFR was examined in 37 women with breast cancer who had been treated with surgical resection. Relationship of EGFR expression and clinicopathological characteristics was investigated. Results: EGFR expression proved to be comparatively more frequent among triple-negative (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative) breast cancers (P = 0.067). Conclusions: Knowledge of a patient's immunohistochemical EGFR expression, which could be one of the key molecular findings related to molecular-targeting therapy, might be useful information to treat triple-negative breast cancer.

AB - Background: Molecular-targeting drugs able to treat breast cancer expressing epidermal growth factor receptor (EGFR) would be clinically valuable. The aim of the current study was to determine the further significance of immunohistochemical expression of EGFR in breast cancer. Methods: The immunohistochemical expression of EGFR was examined in 37 women with breast cancer who had been treated with surgical resection. Relationship of EGFR expression and clinicopathological characteristics was investigated. Results: EGFR expression proved to be comparatively more frequent among triple-negative (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative) breast cancers (P = 0.067). Conclusions: Knowledge of a patient's immunohistochemical EGFR expression, which could be one of the key molecular findings related to molecular-targeting therapy, might be useful information to treat triple-negative breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=79251648383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251648383&partnerID=8YFLogxK

U2 - 10.1007/s12282-010-0200-2

DO - 10.1007/s12282-010-0200-2

M3 - Article

VL - 18

SP - 37

EP - 41

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 1

ER -